Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors

British Journal of Cancer

Volumn 90, Issue 3, 2004, Pages 566-572

  Blackledge, G ^a   Averbuch, S ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Cetuximab; EGFR targeting agents; Erlotinib; Gefitinib

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IMC C 225; IRINOTECAN; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; QUINAZOLINE DERIVATIVE; TAMOXIFEN;

ACNE; ALLERGIC REACTION; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ASEPTIC MENINGITIS; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPNEA; EPIGLOTTITIS; FEVER; HEAD AND NECK CARCINOMA; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MACULOPAPULAR ACNEIFORM RASH; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NAUSEA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; RETINA DISEASE; SHORT SURVEY; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 1542329185     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601550     Document Type: Short Survey

References (63)

1. Abid SH, Malhotra V, Perry MC (2001) Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 13: 242-248
2. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110-124
3. Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl 4): 31-39
4. Baselga J (2002) Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7(Suppl 4): 2-8
5. Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Gonzalez S, Guillen V, Sauleda S, Averbuch S, Rojo F (2003) Phase II and tumor pharmacodynamic study of gefitinib (ZD1839) in patients with advanced breast cancer. Oral presentation at ASCO. Proc Am Soc Clin Oncol 22: 7 (abstr 24)
6. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J (2000) Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18: 904-914
7. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292-4302
8. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F (2002) Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8: 3250-3258
9. Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carr B, Hicklin DJ, Bohlen P, Raisch KP (2002) Treatment of pancreatic cancer xenografts with erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 54: 1180-1193
10. Burtness BA, Li Y, Flood W, Mattar BI, Forastiere AA (2002) Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). Proc Am Soc Clin Oncol 21: 226a (abstr 901)
11. Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH (2002) What is a clinically meaningful change on the functional assessment of cancer therapy-lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 55: 285-295
12. Cho CD, Fisher GA, Halsey J, Jambalos CN, Advani RH, Wakelee H, Lum BL, Sikic BI (2003) A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with unresectable or metastatic colorectal cancer. Poster presented at the ASCO, Chicago, IL, May 31-June 3. Poster number 1062
13. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6: 2053-2063
14. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958-2970
15. Cohen EEW, Rosen F, Stadler WM, Recant W, Stanson K, Huo D, Vokes EE (2003a) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980-1987
16. Cohen EEW, Stenson K, Gustin DM, Lamont E, Mauer AM, Blair E, Stadler WM, Dekker A, Mallon W, Vokes EE (2003b) A phase II study of 250-mg gefitinib (ZD1839) monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 22: 502 (abstr 2021)
17. Cohen RB (2003) Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer 2: 246-251
18. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Van Cutsem E (2003) Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 22: 252 (abstr 1012)
19. Douillard J-Y, Natale R, Giaccone G, Lynch T, Nakagawa K, Brahmer J, Averbuch S, Kay A (2002) Gefitinib ('Iressa', ZD1839) provides clinically significant antitumor activity and improves disease-related symptoms in pretreated patients with advanced non-small-cell lung cancer: results of two Phase II trials (IDEAL 1 and IDEAL 2). Poster presented at the EORTC-NCI-AACR. Poster number 177
20. Finkler N, Gordon A, Crozier M, Edwards R, Figueroa J, Garcia A, Hainsworth J, Irwin D, Silberman S, Allen L, Ferrante K, Fisher D, Nadler P (2001) Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc Am Soc Clin Oncol 20: 208a (abs 831)
21. Forsythe B, Faulkner K (2003) Safety and tolerability of gefitinib ('Iressa', ZD1839) in advanced NSCLC: overview of clinical experience. Poster presented at the ERS 13th Annual Congress, Vienna, Austria, September 27-October 1. Poster number P327
22. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong R-P, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246
23. Gatzemeier U, Rosell R, Ramlau R, Robinet G, Szczesna A, Quoix E, Font A, Jimenez E, Mueser M, Harstrick A (2003) Cetuximab (C225) in combination with cisplatin/vinorelbine vs. cisplatin/vinorelbine alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22: 642 (abstr 2582)
24. Giaccone G, Johnson DH, Manegold C, Scagliotti GV, Rosell R, Wolf M, Rennie P, Ochs J, Averbuch S, Fandi A (2002) A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 13(Suppl 5): 2 (abstr 40)
25. Gonzalez-Larriba JL, Giaccone G, van Oosterom AT, Alfonso R, Smit EF, Martens M, Peters GJ, Van Der Vijgh WJF, Smith R, Fandi A, Averbuch S (2002) ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemonaive patients with advanced solid tumors: final results of a phase I trial. Poster presented at the ASCO, Orlando, FL, 18-21 May. Poster number 376
26. Herbst RS, Hong WK (2002) IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin Oncol 29: 18-30
27. Herbst RS, Kies MS (2002) ZD1839 (Iressa™) in non-small cell lung cancer. Oncologist 7(Suppl 4): 9-15
28. Herbst RS, Langer CJ (2002) Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 29: 27-36
29. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20: 3815-3825
30. Huang SM, Li J, Armstrong EA, Harari PM (2002) Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62: 4300-4306
31. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361: 137-139
32. Johnson DH, Herbst R, Giaccone G, Schiller J, Natale RB, Miller V, Wolf M, Helton A, Averbuch S, Grous J (2002) ZD1839 ('Iressa') in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol 13(Suppl 5): 127 (abstr 4680)
33. Kawasaki H, Nagai K, Yoshida J, Nishimura M, Nishiwaki Y (2002) Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol 81: 33-37
34. Kies MS, Harari PM (2002) Cetuximab (ImClone/Merck/Bristol-Myers Squibb). Curr Opin Investig Drugs 3: 1092-1100
35. Kim TE, Murren JR (2002) Erlotinib OSI/Roche/Genentech. Curr Opin Investig Drugs 3: 1385-1395
36. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belini CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy and safety of gefitinib (Iressa, ZD1839), an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with advanced non-small cell lung cancer. JAMA 290: 2149-2158
37. Magne N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange J-L, Milano G (2002) Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86: 819-827
38. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6: 701-708
39. Miller VA, Johnson D, Heelan RT, Pizzo BA, Perez WJ, Bass A, Kris MG, Ochs J, Averbuch S (2001) A pilot trial demonstrates the safety of ZD1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20: 326a (abstr 1301)
40. Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose M, Dong R-P, Fukuoka M (2003) Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumours. Ann Oncol 14: 922-930
41. Natale RB, Zaretsky SL (2002) ZD1839 (Iressa™): what's in it for the patient? Oncologist 7(Suppl 4): 25-30
42. Needle MN (2002) Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 29: 55-60
43. Normanno N, Campiglio M, De Luca A, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S (2002) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13: 65-72
44. O'Dwyer PJ, Benson AB (2002) Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol 29: 10-17
45. Patel JD, Miller VA, Kris MG, Shah NT, Pizzo B, Tyson L, Zakowski M, Memoli N, Heelan R, Johnson DH (2003) Encouraging activity and durable responses demonstrated by the epithelial growth factor receptor-tyrosine kinase inhibitor, erlotinib (Tarceva TM, OSI774), in patients with advanced bronchioloalveolar (BAC) cell carcinoma. Lung Cancer 41(Suppl 2): S56 (abstr O-188)
46. Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, Rowinsky E, Preston G, Ferrante KJ, Allen LF, Nadler PI, Bonomi P (2001) A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20: 310a (abstr 1235)
47. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ (2003) Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8: 994-1003
48. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK (2002) ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20: 2240-2250
49. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW (2001) Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19: 3234-3243
50. Robertson JFR, Gutteridge E, Cheung KL, Owers R, Koehler M, Hamilton L, Gee J, Nicholson RI (2003) Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study. Oral presentation at ASCO. Proc Am Soc Clin Oncol 22: 7 (abstr 23)
51. Schiller J, Eek R, Hammond L, Horai T, Gandara D, Noda K, Averbuch S, Wolf M, Kay A, Lowe E (2003) Targeting the epidermal growth factor receptor tyrosine kinase with gefitinib ('Iressa', ZD1839): preliminary investigations of baseline factors associated with response in patients with advanced non-small-cell lung cancer. Poster presented at the Molecular Targets for Cancer Therapy. Poster number 314
52. Schiller JH, Fukuoka M, Natale R, Lynch T, Averbuch S, Kay A (2002) Results from two phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 ('Iressa') in patients with locally advanced or metastatic non-small-cell lung cancer. Poster presented at the Chest Congress. Poster number 372
53. Senzer NN, Soulieres D, Siu L, Agarwala S, Vokes E, Hidalgo M, Silberman S, Allen L, Ferrante K, Fisher D, Marsolais C, Nadler P (2001) Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 20: 2a (abstr 6)
54. Shin DM, Donato NJ, Perez-Soler R, Shin HJC, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK (2001) Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7: 1204-1213
55. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885-4892
56. Siu LL, Hidalgo M, Nemunaitis J, Rizzo J, Moczygemba J, Eckhardt SG, Tolcher A, Smith L, Hammond L, Blackburn A, Tensfeldt T, Silberman S, Von Hoff DD, Rowinsky EK (1999) Dose and schedule-duration escalation of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358, 774: a phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol 18: 388a (abstr 1498)
57. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C (2003) EGFR blockade with ZD1839 ('Iressa') potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Int J Radiat Oncol Biol Phys 55: 713-723
58. Tortora G, Caputo R, Damiano V, Fontanini G, Melisi D, Veneziani BM, Zunino F, Bianco AR, Ciardiello F (2001) Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin Cancer Res 7: 4156-4163
59. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754
60. West HL, Franklin WA, Gumerlock P, Vance RB, Lau DHM, Chansky K, Crowley J, McCoy J, Gandara DR (2003) ZD1839 (Iressa) in advanced bronchioloalveolar carcinoma (BAC): a preliminary report of SWOG S0126. Lung Cancer 41(Suppl 2): S56 (abstr O-187)
61. Williams KJ, Telfer BA, Stratford IJ, Wedge SR (2002) ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86: 1157-1161
62. Woodburn JR, Kendrew J, Fennell M, Wakeling AE (2000) ZD1839 ('Iressa') a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK1): inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition. Proc Am Assoc Cancer Res 41: 402 (abstr 2552)
63. Xu JM, Azzariti A, Colucci G, Paradiso A (2003) The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol 52: 442-448